Full-Time

Project Manager

Portfolio Operations

Confirmed live in the last 24 hours

Sanofi

Sanofi

10,001+ employees

Global healthcare provider of medicines and vaccines

Senior

Bridgewater Township, NJ, USA

Hybrid capacity; home office in Bridgewater, NJ (Morristown, NJ in 2025)

Category
Project Management
Business & Strategy
Requirements
  • Minimum of five (5+) years of US pharmaceutical or vaccine marketing or marketing operations experience.
  • Process skills and great attention to detail.
  • Strong creative problem-solving and decision-making skills.
  • Proactive leadership and collaboration skills to establish strong networks.
  • Passion for transformation and modernization; a strong desire and curiosity to continuously learn and improve self and others.
  • Strong organizational awareness; ability to navigate, leverage, collaborate and deliver results within the matrix and operating culture.
  • Excellent written and oral communication/presentation skills in English.
Responsibilities
  • Lead the execution of the US Vaccines TTT and POA national, regional, and/or divisional sales meetings.
  • Forecast and manage the annual sales meeting budget and optimize the spend by finding efficiencies, cost savings, and cost avoidances.
  • Partner and collaborate with the other US BU meeting planning teams to ensure best practices are continuously shared and transversal operations are leveraged.
  • Coordinate the annual US Vaccines Virtual Awards event.
  • Be a renowned and credible “go-to” subject matter expert (SME) on sales meeting planning and execution, coaching and sharing knowledge when and where required.
  • Stay updated with the latest trends and best practices in sales meeting logistics.
  • Leading the execution and coordination of the US HCP congress and convention strategy for the US Vaccines BU.
  • Partner and collaborate with the other US BU convention teams to ensure a One Sanofi approach (when appropriate), best practices are continuously shared, and transversal operations are leveraged.
  • Serve as resolution point for Transparency (Federal and State) Reporting and Compliance problem escalations that cannot be resolved at the Hub level.
  • Serve as RCQ Standards (Reach/Cost/Quality) point for US Vaccines. Liaison with Procurement and Finance on RCQ Standards initiatives.
  • Demonstrate the ability to successfully work in a matrixed organization.
  • Foster a collaborative and innovative culture within the US Vaccines Portfolio Strategy and Marketing Operations Team.
Desired Qualifications
  • Minimum of five (5+) years US vaccine marketing operations experience.
  • Strong understanding of Sanofi internal processes and systems.

Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical needs. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, allowing it to maintain a diverse product pipeline. The company's goal is to enhance health outcomes and improve the quality of life for people globally.

Company Size

10,001+

Company Stage

IPO

Total Funding

$2B

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Dupixent's potential approval could make it the first targeted treatment for bullous pemphigoid.
  • Sarclisa's expanded approval offers new revenue streams in the oncology market.
  • Sanofi's €5 billion share buyback program indicates strong financial health.

What critics are saying

  • Increased competition in multiple myeloma treatments may impact Sarclisa's market share.
  • €5 billion share buyback could limit capital for R&D investments.
  • Regulatory challenges may delay approval of new drugs like Tolebrutinib.

What makes Sanofi unique

  • Sanofi's Dupixent shows promise in treating bullous pemphigoid, a rare skin disease.
  • Sarclisa's approval in Japan and EU strengthens Sanofi's oncology portfolio.
  • Sanofi's partnership with BrightInsight enhances digital health solutions for specialty therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

PharmiWeb
Mar 10th, 2025
Dupixent Late-Breaking Positive Pivotal Data In Bullous Pemphigoid Presented At Aad

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itchDupixent also significantly reduced oral corticosteroid and rescue medicine use compared to placeboData support the potential of Dupixent to be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying type 2 inflammation; regulatory submissions are under review in the US and the EUParis and Tarrytown, NY, March 8, 2025. Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting. BP is a chronic, debilitating, and relapsing skin disease with underlying type 2 inflammation and characterized by intense itch and blisters, reddening of the skin, and painful lesions.Victoria Werth, MDChief of the Division of Dermatology at the Philadelphia Veterans Administration Hospital, Professor of Dermatology and Medicine at the Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, and principal investigator of the study“People with bullous pemphigoid live with unrelenting itch, blisters, and painful lesions that can be debilitating and make it difficult to function daily. Moreover, current treatment options can be challenging for this primarily elderly patient population because they work by suppressing their immune system. By targeting the underlying type 2 inflammation, which is a key driver for bullous pemphigoid, Dupixent is the first investigational biologic to show sustained disease remission and reduce disease severity and itch compared to placebo in a clinical study.”The ADEPT study met all primary and key secondary endpoints, enrolling 106 adults with moderate-to-severe BP who were randomized to receive Dupixent 300 mg (n=53) every two weeks after an initial loading dose or placebo (n=53) added to standard-of-care oral corticosteroids (OCS). During treatment, all patients underwent a protocol-defined OCS tapering regimen if control of disease activity was maintained

Sanofi
Mar 7th, 2025
Press release: Sanofi successfully prices EUR 1.5 billion of bond issue

Sanofi successfully prices EUR 1.5 billion of bond issue  Paris, March 5, 2025. Sanofi announces that it has successfully priced its offering of EUR 1.5 billion of notes across 2 tranches: €850...

Finsmes
Feb 27th, 2025
Enveda Receives Investment from Sanofi; Brings Total Series C Financing to $150M

Enveda, a Boulder, CO-based biotechnology company empowering life’s chemistry to discover new medicines, received an investment from Sanofi, bringing the total of Series C funding to $150M

PharmiWeb
Feb 25th, 2025
Sarclisa Approved In Japan For Patients With Newly Diagnosed Multiple Myeloma

Approval offers access to new treatment options for newly diagnosed MM patientsApproval based on positive results from the IMROZ phase 3 study that demonstrated Sarclisa in combination with VRd significantly improved progression-free survival, compared to VRd alone in transplant-ineligible newly diagnosed multiple myelomaParis, February 25, 2025. The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) based on data from the IMROZ phase 3 study.Olivier NatafGlobal Head, Oncology“In recent years, new multiple myeloma cases have increased steadily in Japan and other Asian-Pacific nations, creating a need for new treatment approaches, particularly in the front-line setting. While Sarclisa-based combinations have been approved for relapsed or refractory patients in Japan, this approval represents the first indication for certain newly diagnosed patients. We are pleased to offer physicians an important new option for their patients earlier in the treatment journey, building upon our continued commitment to advancing innovative oncology treatments in difficult-to-treat hematologic malignancies around the world.”In Japan, Sarclisa was launched in August 2020 and has been approved for four different treatment regimens (in combination with pomalidomide and dexamethasone, as monotherapy, in combination with carfilzomib and dexamethasone, or in combination with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma). In addition, Sarclisa has front-line approvals in the EU and the US. In the Asia Pacific region, Sarclisa combination regimens were also recently approved by the National Medical Products Administration in China, specifically Sarclisa-VRd in NDMM patients who are not eligible for autologous stem cell transplant, as well as Sarclisa in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients with relapsed or refractory MM who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor.About SarclisaSarclisa (isatuximab) is a CD38 monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct antitumor activity

Webrazzi
Feb 17th, 2025
Sanofi Pharmup Girişimcilik Programı’Nın 6. Dönemi Için Başvurular Başladı! [Sponsorlu İçerik]

Sanofi’nin sağlık sektöründe katma değer yaratacak yenilikçi fikirlerin gelişimine destek olmak için Endeavor ile birlikte hayata geçirdiği Girişimcilik Programı PharmUp’ın 6. dönem başvuruları başladı.Türkiye’nin girişimcilik alanındaki köklü kurumlarından Endeavor iş birliğinde gerçekleşecek 6. dönem takvimine göre, başvurular 25 Şubat 2025 tarihine kadar sanofi.com.tr/tr/pharmup üzerinden yapılabilecek. Yeni dönemin kategorileri Akıllı Sağlık Cihazları ve Diagnostik Çözümler (giyilebilir teknolojiler ve hızlı test araçları), Medikal Eğitim ve İletişim Araçları, Sağlıklı Yaşam Çözümleri, Dijital Sağlık ve Teletıp, Veri Yönetimi ve Analitiği, Kurumsal Dijital Dönüşüm olarak belirlendi.Sağlık sektöründe hastaların hayatını iyileştirme adına dijital çözümler üreten fikirlerin hayat bulduğu program PharmUp’ta seçilecek girişimler, mentorluk desteği ve eğitimler içeren 3 aylık hızlandırma dönemine başlayacak. Bu süreçte ürünlerini olgunlaştıran start-up’lar, sonrasında gerçekleştirilecek Demo Day ile sektörün önde gelen isimlerine projelerini tanıtma şansı bulacak ve Sanofi ile iş birliği fırsatı sunulacak. Bunlara ek olarak, programa katılacak girişimciler arasından belirlenecek kişiler, Paris’te gerçekleşen Viva Technology Fuarı’na Sanofi sponsorluğunda katılma imkânı bulacak.PharmUp’ta 2019’dan beri 27 girişimciye destek verildiİlki 2019 yılında gerçekleşen programa, bugüne kadar toplamda 300’e yakın girişimci başvuru yaptı